Loading
Tryptophan and Brain Disorders / Immune Cells in Cancer · Journal article
Frontiers in Cellular and Infection Microbiology · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a conceptual framework paper that reorganizes published single-cell transcriptomic data from bacterial pneumonia into six ranked 'treatable cell states' (macrophage, neutrophil, T-cell, epithelial, stromal, and one additional category) to guide future host-directed therapy research. The authors explicitly state that most proposed interventions remain at the hypothesis stage and require longitudinal, functional, and protein-level validation before clinical translation.
Narrative review and conceptual reorganization of published datasets. Patients with bacterial pneumonia and related lung infections represented in published single-cell atlases from bronchoalveolar lavage fluid and peripheral blood; specific cohort sizes and eligibility not detailed.
Severity-linked expansion of IDO1+/PD-L1+ macrophages and pathological neutrophils shows strongest current evidence Exhausted-like CD8+ T-cell states have emerging human transcriptomic support but lack protein-level and functional validation Evidence for injured epithelium and repair-failed stromal states remains partly inferential, drawing on adjacent lung-injury literature
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This framework is intended to guide prioritization of host-directed therapy targets for future research rather than to inform current clinical practice. Clinicians should recognize these as candidate mechanisms requiring validation, not established therapeutic targets.
A narrative reorganization of published single-cell datasets proposing a ranked hypothesis framework for host-directed therapy targets in bacterial pneumonia, without new primary data, validation, or clinical outcome evidence.
As stated by the source record.
Quoted from the source exactly as published.
This framework is intended to guide prioritization of host-directed therapy targets for future research rather than to inform current clinical practice. Clinicians should recognize these as candidate mechanisms requiring validation, not established therapeutic targets.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Bacterial pneumonia remains a major cause of infectious mortality, and antimicrobial resistance has intensified interest in host-directed therapy (HDT). Recent bronchoalveolar lavage fluid (BALF) and peripheral blood atlases (2024–2025) provide single-cell evidence from human disease, but the main translational gap is prioritization rather than catalog expansion. In this review, we reorganize published datasets from bacterial pneumonia and related lung infection cohorts (>500,000 cells; 2020–2026) into a state-prioritization scheme termed “treatable cell states.” Evidence is currently strongest for severity-linked expansion of indoleamine 2,3-dioxygenase 1–positive/programmed death-ligand 1–positive (IDO1+/PD-L1+) macrophages and pathological neutrophils; exhausted-like CD8+ T-cell states show emerging human transcriptomic and translational support but still require protein-level, functional, and longitudinal validation, whereas evidence for injured epithelium and repair-failed stromal states in bacterial pneumonia remains partly inferential and draws on adjacent lung-injury literature. We therefore treat the six proposed state categories as a ranked hypothesis set for macrophage-, neutrophil-, T-cell-, epithelial-, and stromal-directed interventions, not as validated clinical targets. Most proposed interventions still require longitudinal and functional validation before routine bedside use.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.